Combination of [<sup>18</sup>F]FDG and [<sup>18</sup>F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 38200396.
- Also identified by DOI 10.1007/s00259-023-06585-7.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
[<sup>18</sup>F]fluorodeoxyglucose ([<sup>18</sup>F]FDG) positron emission tomography/computed tomography (PET/CT) has limitations in prostate cancer (PCa) detection owing to low glycolysis in the primary tumour. Recently, prostate-specific membrane antigen (PSMA) PET/CT has been useful for biochemical failure detection and radioligand therapy (RLT) guidance. However, few studies have evaluated its use in primary prostate tumours using PSMA and [<sup>18</sup>F]FDG PET/CT. This study aimed to evaluate [<sup>18</sup>F]PSMA-1007 and [<sup>18</sup>F]FDG PET/CT for primary tumour detection and understand the association of metabolic heterogeneity with clinicopathological characteristics at staging and postoperatively. This prospective study included 42 index tumours (27 acinar and 15 ductal-dominant) in 42 patients who underwent [<sup>18</sup>F]PSMA-1007 and [<sup>18</sup>F]FDG PET/CT and subsequent radical prostatectomy. All patients were followed for a median of 26 mo, and serum prostate-specific antigen levels were measured every 3 mo to evaluate biochemical failure. One-way analysis of variance, Tukey's multiple comparison test, and Fisher's exact test were performed. All 42 index tumours were detected on [<sup>18</sup>F]PSMA-1007 PET/CT, whereas only 15 were detected on [<sup>18</sup>F]FDG PET/CT (62.3% vs. 37.7%, p < 0.0001). A high SUV<sub>max</sub> for [<sup>18</sup>F]PSMA-1007 was observed in tumours with high Gleason scores (GS 6-7 vs. GS 8-10; 12.1 vs. 20.1, p < 0.05). Tumours with [<sup>18</sup>F]FDG uptake were mostly ductal dominant (acinar-dominant 4/27; ductal-dominant; 11/15, p < 0.001), with lower [<sup>18</sup>F]PSMA-1007 uptake than tumours without [<sup>18</sup>F]FDG uptake (SUVmax 16.58 vs. 11.19, p < 0.001). There were 16.6% (7/42) of patients with pStage IV in whom the primary tumours were [<sup>18</sup>F]FDG positive. Biochemical failure was observed in 14.8% (4/27) of patients with [<sup>18</sup>F]FDG negative tumours but in 53.3% (8/15) of patients with [<sup>18</sup>F]FDG positive tumours (p = 0.013). [<sup>18</sup>F]PSMA-1007 PET/CT was superior to [<sup>18</sup>F]FDG PET/CT in detecting primary PCa. In contrast, tumours with [<sup>18</sup>F]FDG uptake are associated with larger size, a ductal-dominant type, and likely to undergo metastasis at staging and biochemical failure postoperatively.
Medical subject headings
- Positron Emission Tomography Computed Tomography
- Prostatic Neoplasms
- Fluorodeoxyglucose F18
- Neoplasm Staging
- Niacinamide